David Dodd Biography and Net Worth

David has served as the President and CEO of GeoVax Labs, Inc. since 2018.  He joined the GeoVax Board of Directors in March 2010 and was elected Chairman in January 2011.

Mr. Dodd has led GeoVax through a corporate recapitalization and up-listing to Nasdaq, followed by the Company rapidly transforming from a preclinical  to clinical development status, having received an expedited registration path from the EMA (European Medicines Agency) for GEO-MVA, a mpox/smallpox vaccine.  This vaccine is scheduled to initiate a pivotal Ph 3 trial in Q4 2026, with results anticipated by mid-2027 and potential commercialization by mid-2028.

In addition, the Company is developing  Gedeptin^®, a cancer immunotherapy, having received Orphan Drug designation from the FDA.  Successfully completing Phase 1 and Phase 1/2b studies, the Company plans to initiate a Phase 2 study during 2027, combining Gedeptin with an immune checkpoint inhibitor, as therapy against first line head and neck cancer.

In addition, David has focused on significant strengthening of corporate governance, Board development and organizational capabilities.

During his career, he has overseen the approval of over 10 NDAs, over 15 acquisitions/divestitures, in excess of $2.5 billion in financial transactions, and over $5 billion in incremental enterprise growth. His achievements also include successful IPO listings, re-capitalizations, and corporate developments in multiple international jurisdictions.

During David’s six-year tenure as President, CEO, and Director of Serologicals Corporation, Nasdaq: SERO, the market-value increased from $85 million to $1.5 billion, during which he brokered an all-cash sale to Millipore Corporation.  While serving as President, CEO & Director of Solvay Pharmaceuticals, Inc., the enterprise-value increased over five years from $100 million to $2.5 billion.

David also served in General Management executive roles with Wyeth, now part of Pfizer, Bristol-Myers Squibb, and Abbott Laboratories.  He earned Bachelor of Science and Master of Science degrees from Georgia State University and completed the Advanced Management Program of Harvard Business School.

He is a frequent invited speaker and panelist at business and economic development conferences, as well as various conferences focused on the life sciences and pharmaceutical industry.  David is a recipient of the Oglethorpe Award for UK-US Business Relationships recognized by the British American Business Council, the Georgia BIO Industry Growth Award, and a multi-year recipient of the FastTech 50 Growth Company Award (2000-2006) while leading Serologicals Corporation.  In 2011, he was recognized by Georgia State University, receiving the Distinguished Alumni Achievement Award.

In addition, he has served on a development committee of the MacArthur Foundation, as an advisor to the First Minister of Scotland, as the Chair of the American Foundation for Suicide Prevention, as a member of the External Advisory Board of the Petit Institute for Bioengineering & Biosciences (GaTech), as the Chair of GaBio, as a board member on the Harvard Business School Healthcare Alumni Association and, in leadership roles with numerous additional organizations.  David is an active member of BIO (Biotechnology Innovation Organization), serving on the Vaccine Policy Steering Committee and the Biodefense Policy Steering Committee.  He has also served as the Vice-Chair of the Executive Committee of the Medical CBRN (Chemical, Biological, Radiological and Nuclear) Defense Consortium.